Press Release

Atomwise recognized for achievements in AI-driven drug discovery and creation of the AtomNet® platform, which has tackled — and succeeded in — finding small molecule hits for more undruggable targets than any other platform

NEW YORK, August 13, 2020 -- CB Insights today named Atomwise to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. 

The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care. Countries represented this year include Canada, China, Israel, France, the United Kingdom, and the United States, among others. 

“This year’s Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more,” said CB Insights CEO Anand Sanwal. “Last year’s Digital Health 150 winners saw numerous exits and went on to raise nearly $5 billion in investor financing after being recognized. We look forward to seeing the success of this year's class of the best in digital health."  

Atomwise created the first convolutional neural networks (CNN) for drug discovery. Since its founding in 2012 the company has continually developed and improved its AI-based drug discovery technology, called AtomNet®, which can screen over 16 billion synthesizable molecules against biological targets with little-to-no structural information in less than two days. With AtomNet technology the company can rapidly discover promising candidate molecules to develop as potential drugs for currently untreatable disease. Importantly, we can also initiate multiple drug target programs simultaneously and at scale, either as part of the company's discovery pipeline and growing portfolio of joint venture companies (JVs), or as co-development partnerships with biotechnology and pharmaceutical companies. Earlier this week, the company announced it has closed a $123 million Series B financing round led by B Capital Group and Sanabil Investments, bringing the total amount of capital raised to date to almost $175 million.

“We’re honored to be recognized by CB Insights alongside other notable companies making an impact in the digital health space,” said Abraham Heifets, CEO and co-founder of Atomwise. “With our latest funding, Atomwise is entering a new phase of growth that allows us to strengthen our work with corporate partners and joint ventures, as well as develop our own drug discovery pipeline to help address huge unmet needs for human disease.”

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights’ algorithm, measures the overall health and growth potential of private companies to help predict a company’s momentum. 

Quick facts on the 2020 Digital Health 150:

• The 2020 Digital Health 150 startups have raised over $20B in funding across 600+ deals from 900+ unique investors.
• The list includes 12 unicorns (companies that have reached a valuation of $1B+) focused on a diverse range of digital health solutions, including telehealth, insurance, and robotic surgical systems.
• Many have formed partnerships with key industry players like the American Heart Association, Cigna, and Mount Sinai Health System. 

About CB Insights

At CB Insights, we believe the most complex strategic business questions are best answered with facts.  We are a machine intelligence company that synthesizes, analyzes and visualizes millions of documents to give our clients fast, fact-based insights. Serving the majority of the Fortune 100, we give companies the power to make better decisions, take control of their own future, and capitalize on change.

Contact:
Keith Swiader, Manager - PR & Communications
[email protected]
917-214-1028

About Atomwise

Atomwise Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today, Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. AtomNet®, its AI platform built for drug discovery contains more than 16 billion molecules for virtual screening. Atomwise has raised over $174 million from leading venture capital firms to support the development and application of its AI technology. Learn more at atomwise.com or follow @AtomwiseInc.

Atomwise Contact:
Sara Agee Le, PhD
Vice President of Marketing and Communications
[email protected]
[email protected]